证券代码：002901 证券简称：大博医疗 公告编号：2025-037 大博医疗科技股份有限公司 第三届董事会第十九次会议决议公告 本议案提交董事会前已经公司董事会薪酬与考核委员会 2025 年第二次会议 审议通过，律师就本议案发表了同意结论的意见。 董事罗炯为 2024 年股票期权激励计划的激励对象，对该议案回避表决。 具体内容详见 2025 年 9 月 18 日刊登在指定信息披露媒体及巨潮资讯网 （www.cninfo.com.cn）上的《关于调整 2024 年股票期权激励计划行权价格的公 告》及《关于大博医疗科技股份有限公司 2024 年股票期权激励计划预留授予及 调整行权价格事项的法律意见书》。 二、会议以 7 票赞成、0 票反对、0 票弃权的表决结果审议通过了《关于向 激励对象授予预留股票期权的议案》。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 大博医疗科技股份有限公司（以下简称"公司"）第三届董事会第十九次会 议于2025年9月17日在公司会议室以现场及通讯相结合方式召开，会议通知以专 人送达、传真、电子邮件、电话相结合的方式已于2025年9 ...

Core Viewpoint - The stock of Dabo Medical (002901) has shown a slight increase in price, with significant net inflows from retail investors despite overall net outflows from institutional and speculative funds [1][2]. Financial Performance - Dabo Medical reported a total revenue of 1.21 billion yuan for the first half of 2025, representing a year-on-year increase of 25.55% [3] - The net profit attributable to shareholders was 244 million yuan, up 76.69% year-on-year [3] - The company's gross profit margin stands at 71.01%, significantly higher than the industry average of 51.85% [3] - The second quarter of 2025 saw a single-quarter revenue of 660 million yuan, a 22.96% increase year-on-year, with a net profit of 141 million yuan, reflecting an 84.47% increase [3] Market Position - Dabo Medical's total market capitalization is 23.119 billion yuan, ranking 10th in the medical device industry [3] - The company has a price-to-earnings ratio of 47.32, which is lower than the industry average of 67.38, indicating a relatively favorable valuation [3] - The return on equity (ROE) is 7.6%, significantly higher than the industry average of 1.8%, showcasing effective management of equity [3] Fund Flow Analysis - On September 11, 2025, the stock experienced a net outflow of 29.5822 million yuan from institutional investors, accounting for 14.33% of the total trading volume [1][2] - Retail investors contributed a net inflow of 34.4472 million yuan, representing 16.69% of the total trading volume on the same day [1][2] - Over the past five days, the stock has seen fluctuating fund flows, with notable retail investor activity during periods of price decline [2]

证券之星消息，截至2025年9月10日收盘，大博医疗(002901)报收于55.74元，上涨0.02%，换手率 0.98%，成交量2.84万手，成交额1.58亿元。 9月10日的资金流向数据方面，主力资金净流出551.75万元，占总成交额3.48%，游资资金净流入391.93 万元，占总成交额2.47%，散户资金净流入159.82万元，占总成交额1.01%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净流入 游资净占比 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-09-10 | 55.74 0.02% | | -551.75万 | -3.48% | 391.93万 | 2.47% | 159.82万 | liv 1.01% | | 2025-09-09 | 55.73 -4.31% | | ● 901.60万 | 3.32% | 676.73万 | 2.49% | -1578.32万 | -5.82% | | 2025-09-08 | 58. ...

从大博医疗十大流通股东角度 9月9日，大博医疗跌5.05%，截至发稿，报55.30元/股，成交2.52亿元，换手率1.54%，总市值228.95亿 元。 资料显示，大博医疗科技股份有限公司位于福建省厦门市海沧区山边洪东路18号，成立日期2004年8月 12日，上市日期2017年9月22日，公司主营业务涉及医用高值耗材的生产、研发与销售。主营业务收入 构成为：创伤类产品38.68%，脊柱类产品17.95%，微创外科类产品16.34%，关节类产品10.37%，其他 产品9.27%，神经外科类产品4.50%，齿科类产品2.89%。 数据显示，南方基金旗下1只基金位居大博医疗十大流通股东。南方中证1000ETF（512100）二季度增 持14.19万股，持有股数75.68万股，占流通股的比例为0.26%。根据测算，今日浮亏损失约222.49万元。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 南方中证1000ETF（512100）基金经理为崔蕾。 截至发稿， ...

Group 1 - The medical device sector is experiencing significant growth, with the CSI All Index Medical Device Index (H30217) rising by 3.31% as of September 8, 2025, and key stocks such as United Imaging Healthcare (688271) increasing by 11.64% [1] - The Medical Device ETF (159883) has seen a notable increase of 8.06 billion CNY in scale over the past month, ranking it among the top 25% of comparable funds [2] - The launch of the "5G Brain-Heart Mobile" platform represents a major breakthrough in the field of brain health, marking the first clinical application of a brain-machine interface for Alzheimer's disease [3] Group 2 - The Chinese medical device industry is poised for international expansion, particularly in the European market, which is valued at 160 billion euros in 2023, with steady growth expected [4] - The medical device sector is anticipated to grow in 2025, driven by increased bidding activity for imaging equipment and supportive policies for home medical devices, alongside accelerated international expansion [4] - The medical device ETF (159883) is the largest in the A-share market, covering various segments including medical equipment and consumables, and is positioned for efficient trading [5]

Group 1 - The medical device sector experienced a significant upward movement on September 8, with companies such as Aojing Medical, United Imaging Medical, and Kaili Medical seeing stock increases of over 10% [1] - Other companies in the sector, including Jimin Health, BGI Genomics, Dabo Medical, and Mindray Medical, also showed positive stock performance [1]

Core Viewpoint - Dabo Medical (002901) shows a positive performance with a closing price of 54.39 yuan, up 1.76% as of September 5, 2025, despite some net outflows from major and retail investors [1] Financial Performance - Dabo Medical reported a main revenue of 1.21 billion yuan for the first half of 2025, an increase of 25.55% year-on-year [3] - The net profit attributable to shareholders reached 244 million yuan, up 76.69% year-on-year [3] - The net profit excluding non-recurring items was 223 million yuan, reflecting an increase of 82.64% year-on-year [3] - In Q2 2025, the company achieved a single-quarter main revenue of 660 million yuan, up 22.96% year-on-year [3] - The single-quarter net profit attributable to shareholders was 141 million yuan, up 84.47% year-on-year [3] - The single-quarter net profit excluding non-recurring items was 126 million yuan, up 73.04% year-on-year [3] Market Position - Dabo Medical's total market capitalization is 22.519 billion yuan, ranking 11th in the medical device industry [3] - The company's net assets stand at 3.233 billion yuan, ranking 45th in the industry [3] - The net profit margin is 21.42%, ranking 33rd in the industry [3] - The company has a gross margin of 71.01%, significantly higher than the industry average of 51.85% [3] - The price-to-earnings ratio (P/E) is 46.1, which is lower than the industry average of 65.4 [3] Investor Sentiment - As of the last 90 days, one institution has given a buy rating for Dabo Medical [4]

Core Viewpoint - The stock of Dabo Medical (002901) has experienced a decline, with significant net outflows from major and retail investors, while the company shows strong financial performance in its recent earnings report [1][2][3]. Financial Performance - Dabo Medical reported a total revenue of 1.21 billion yuan for the first half of 2025, representing a year-on-year increase of 25.55% [3]. - The net profit attributable to shareholders was 244 million yuan, up 76.69% year-on-year [3]. - The company's second-quarter revenue was 660 million yuan, reflecting a 22.96% increase compared to the same quarter last year [3]. - The gross profit margin stands at 71.01%, significantly higher than the industry average of 51.85% [3]. Market Position - Dabo Medical's total market capitalization is 22.129 billion yuan, ranking 11th in the medical device industry [3]. - The company has a price-to-earnings (P/E) ratio of 45.3, which is lower than the industry average of 65.27 [3]. - The return on equity (ROE) is 7.6%, placing the company 13th in its industry [3]. Recent Trading Activity - On September 4, 2025, Dabo Medical's stock closed at 53.45 yuan, down 1.93% with a trading volume of 31,300 hands and a turnover of 169 million yuan [1]. - The net outflow of major funds on the same day was 8.1177 million yuan, accounting for 4.8% of the total turnover [1][2]. - Retail investors showed a net inflow of 14.7464 million yuan, representing 8.72% of the total turnover [1][2].

Core Insights - The Chinese medical device industry faced challenges and opportunities in the first half of 2025, with a recovery in bidding for medical equipment not yet translating into improved company performance [1][3] - Overall performance of the industry remained under pressure due to complex global macroeconomic conditions, with a decline in revenue and net profit for A-share medical device companies [1][3] Financial Performance - In the first half of 2025, 131 A-share medical device companies reported total revenue of 1188.17 billion yuan, a decrease of 4.29% from 1241.43 billion yuan in the previous year [1] - Net profit for these companies fell to 188.12 billion yuan, down 17.17% from 227.11 billion yuan year-on-year [1] - Over 80% of companies in the in vitro diagnostics sector experienced a decline in performance due to factors like centralized procurement and medical insurance cost control [1] Sector Highlights - Despite overall declines, certain sectors like orthopedics and cardiovascular devices showed significant growth, with companies such as Sanyou Medical and Dabo Medical reporting revenue growth exceeding 40% [1][4] - Sanyou Medical achieved a remarkable net profit growth of 2083.64%, driven by acquisitions and recovery in domestic business [4] International Market Expansion - Overseas markets have become crucial for leading companies to overcome growth bottlenecks, with companies like Ruimai Te and Yuyue Medical reporting revenue growth of 61.33% and 49.96% respectively from international sales [2][7] - The international revenue for 89 companies reached 332.47 billion yuan, marking an 8.2% increase year-on-year [6] Future Outlook - The industry anticipates a turning point in the second half of 2025, with signs of demand recovery and improved bidding activity for medical devices [3][10] - The approval of innovative medical devices and drugs is on the rise, with 45 innovative medical devices approved in the first half of 2025, a year-on-year increase of 87% [12][13]

证券之星消息，截至2025年9月1日收盘，大博医疗(002901)报收于55.78元，上涨1.38%，换手率 1.53%，成交量4.41万手，成交额2.45亿元。 9月1日的资金流向数据方面，主力资金净流入405.47万元，占总成交额1.65%，游资资金净流入859.24 万元，占总成交额3.51%，散户资金净流出1264.71万元，占总成交额5.16%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 游资净占比 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-09-01 | 55.78 | 1.38% | 405.47万 | 1.65% | 859.24万 | 3.51% | -1264.71万 | -5.16% | | 2025-08-29 | 55.02 | 1.40% | = -91.04万 | -0.49% | -165.65万 | -0.89% | 256.69万 | 1.38% | | 2025-08-28 | | 54.26 ...